Related Experiment Video
Updated: Apr 23, 2026

Injection of Porcine Adipose Tissue-Derived Stroma Cells via Waterjet Technology
Published on: November 23, 2021
Maintaining persistence and adherence with subcutaneous growth-hormone therapy in children: comparing jet-delivery
Helen A Spoudeas1, Priti Bajaj2, Nathan Sommerford3
1London Centre for Paediatric Endocrinology, University College London, London, UK.
Insights
The ZomaJet jet-delivery device significantly improved persistence and adherence in children receiving growth hormone (GH) therapy compared to traditional needle-based devices. Offering jet-delivery options may enhance treatment outcomes.
Area of Science:
- Pediatric endocrinology
- Pharmacotherapy adherence
- Medical device technology
Background:
- Subcutaneous growth hormone (GH) therapy in children often suffers from suboptimal persistence and adherence.
- Needle-based delivery devices are the conventional method for administering GH.
Purpose of the Study:
- To evaluate the impact of the ZomaJet jet-delivery device on medication-taking behaviors in children undergoing GH therapy.
- To compare the persistence and adherence rates between ZomaJet and traditional needle-based GH delivery devices.
Main Methods:
- Retrospective cohort study utilizing a UK nationwide database of GH home-delivery schedules (2010-2012).
- Analysis included 6,061 children (≤18 years) receiving somatropin via ZomaJet or six needle-based GH brands.
- Persistence measured by time between first and last home deliveries; adherence analyzed by proportion of days covered for ZomaJet users.
Main Results:
- Significantly longer persistence with GH therapy was observed in ZomaJet users (599 days) compared to needle-based devices (535 days; P<0.001).
- The majority of ZomaJet patients (58%) were adherent; only 5% of all patients switched GH brands.
- ZomaJet users tended to use the device for longer durations before considering a switch.
Conclusions:
- Jet-delivery devices, such as ZomaJet, may be a crucial strategy for improving persistence in pediatric GH therapy.
- Offering jet-delivery devices could lead to better clinical outcomes and cost-efficiency in managing childhood GH deficiency.
- The choice of delivery device significantly influences patient adherence and long-term treatment success.
Purpose:
Persistence and adherence with subcutaneous growth hormone (GH; somatropin) therapy in children is widely acknowledged to be suboptimal. This study aimed to investigate how the use of a jet-delivery device, ZomaJet(®), impacts on medication-taking behaviors compared to needle-based devices.
Materials And Methods:
A retrospective cohort study of children aged ≤18 years was conducted using a UK-based, nationwide database of GH home-delivery schedules. Data were evaluated for the period between January 2010 and December 2012 for 6,061 children receiving either Zomacton(®) (somatropin) via the ZomaJet jet-delivery device or one of six brands of GH all administered via needle-based devices. Persistence was analyzed for patients with appropriate data, measured as the time interval between first and last home deliveries. An analysis of adherence was conducted only for patients using ZomaJet who had appropriate data, measured by proportion of days covered. Brand switches were identified for all patients.
Results:
Persistence with GH therapy was significantly longer in patients using ZomaJet compared to needle-based devices (599 days versus 535 days, respectively, n=4,093; P<0.001); this association was observed in both sexes and across age subgroups (≤10 and 11-16 years). The majority (58%) of patients using ZomaJet were classed as adherent (n=728). Only 297 patients (5%) switched GH brand (n=6,061), and patients tended to use ZomaJet for longer than other devices before switching.
Conclusion:
It appears important that the choice of a jet-delivery device is offered to children prescribed daily GH therapy. These devices may represent a much-needed effective strategy for maintaining persistence with subcutaneous GH administration in children, potentially offering better clinical outcomes and greater cost-efficiency.
Related Concept Videos
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...

